AZ's Farxiga data kicks off race for SGLT2s in heart failure

Positive data for AstraZeneca's Farxiga dapagiflozin could signal the start of what is for now a two horse race to expand the SGLT2 class beyond diabetes and into heart failure. But the real opportunity in the indication may gain clarity next year when a competitor is expected to report data in heart failure patients with preserved ejection

Read the full 577 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers